Patents by Inventor Maxwell Stock
Maxwell Stock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130115177Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditionsType: ApplicationFiled: December 20, 2012Publication date: May 9, 2013Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock, Greg Stock
-
Patent number: 8372884Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: GrantFiled: November 12, 2009Date of Patent: February 12, 2013Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Publication number: 20120328540Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.Type: ApplicationFiled: August 3, 2012Publication date: December 27, 2012Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen
-
Patent number: 8338648Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions.Type: GrantFiled: June 13, 2005Date of Patent: December 25, 2012Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock, Gregory Stock
-
Patent number: 8334413Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions.Type: GrantFiled: December 15, 2010Date of Patent: December 18, 2012Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock
-
Patent number: 8221804Abstract: The invention encompasses novel compositions containing a methylation modifying compound isolated from botanical raw materials, including a fruit of the genus Coffea, and microbial raw materials, methods of making such compositions, and methods of treating or preventing human disease using such compositions. The methylation modifying compound in botanical extracts of the present invention can dramatically increase the level of methylation of PP2A, thus increasing cognitive function, particularly in persons suffering from or prone to developing Alzheimer's disease.Type: GrantFiled: February 3, 2006Date of Patent: July 17, 2012Assignees: Signum Biosciences, Inc., Trustees of Princeton UniversityInventors: Jeffry B. Stock, Maxwell Stock, Haoming Gu, Gregory B Stock, Zhu Li, Peter Michael Wolanin
-
Publication number: 20110117187Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditionsType: ApplicationFiled: December 15, 2010Publication date: May 19, 2011Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock
-
Publication number: 20110118265Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.Type: ApplicationFiled: November 12, 2010Publication date: May 19, 2011Inventors: Jeffry B. Stock, Maxwell Stock
-
Patent number: 7923041Abstract: Disclosed are compositions for promoting general health and well-being, comprising an extract of a botanical raw material, wherein said extract inhibits the carboxyl demethylating activity of a protein phosphatase, and methods of making and using same.Type: GrantFiled: August 3, 2007Date of Patent: April 12, 2011Assignees: Signum Biosciences, Inc., The Trustees of Princeton UniversityInventors: Jeffry Stock, Maxwell Stock, Haoming Gu, Zhu Li, Peter Wolanin
-
Publication number: 20110070296Abstract: Described are compositions for topical application to keratinous tissues or substrates such as skin, or mucosal surfaces. The composition may be used to treat a skin condition or disease. The composition comprises at least one polypeptide and/or lipidated peptide and a carrier.Type: ApplicationFiled: February 25, 2009Publication date: March 24, 2011Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Seung-Yub Lee, Eduardo Perez, Gopal Sarngadharan, Jeffry B. Stock, Maxwell Stock, Michael Voronkov, Peter Wolanin
-
Publication number: 20100247461Abstract: Disclosed are certain complexes of AFC compounds and binding agents. Such complexes are useful, among other things, in the treatment of inflammatory diseases or disorders.Type: ApplicationFiled: January 20, 2010Publication date: September 30, 2010Applicant: Signum Biosciences, Inc.Inventors: Michael Voronkov, Jeffry B. Stock, Maxwell Stock, Seung-Yub Lee, Eduardo Perez, Joel S. Gordon
-
Patent number: 7794965Abstract: The invention relates to methylated proteins that control protein phosphorylation, particularly phosphoesterases, such as PP2A. It relates to screening methods for determining agents that affect methylation of these proteins and thus also modulate the level of phosphorylation of phosphoproteins. It relates as well to the agents and to compositions comprising the agents. In a particular aspect in this regard the invention relates to agents that alter PP2A methylation and that thereby affect phosphorylation of phosphoproteins that play an important role in health or disease, such as the tau protein which is implicated in the etiology of Alzheimer's Disease. The invention further relates to diagnostic methods based on protein methylation levels, to compositions comprising agents for affecting methylation of proteins and for controlling the phosphate complement of phosphoproteins.Type: GrantFiled: March 13, 2003Date of Patent: September 14, 2010Assignees: Signum Biosciences, Inc., The Trustees of Princeton UniversityInventors: Gregory Stock, Jeffry B. Stock, Maxwell Stock, Scott Vafai
-
Publication number: 20100184768Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: ApplicationFiled: November 12, 2009Publication date: July 22, 2010Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Publication number: 20090264496Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.Type: ApplicationFiled: April 21, 2009Publication date: October 22, 2009Inventors: Scott Vafai, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
-
Publication number: 20090170917Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.Type: ApplicationFiled: December 2, 2008Publication date: July 2, 2009Inventors: Seung-Yub Lee, Eduardo Perez, Keshava Rapole, Gopal Sarngadharan, Gregory B. Stock, Jeffry B. Stock, Maxwell Stock, Michael Voronkov, Peter Wolanin
-
Publication number: 20090155186Abstract: The present invention relates to compositions containing signal transduction modulator compounds, to methods for treating or preventing inflammation, or promoting healthy joints, using the compounds and to kits for the same.Type: ApplicationFiled: June 13, 2006Publication date: June 18, 2009Applicant: SIGNUM BIOSCENCES, INC.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock, Gregory Stock
-
Publication number: 20080213406Abstract: Disclosed are compositions for promoting general health and well-being, comprising an extract of a botanical raw material, wherein said extract inhibits the carboxyl demethylating activity of a protein phosphatase, and methods of making and using same.Type: ApplicationFiled: August 3, 2007Publication date: September 4, 2008Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry Stock, Maxwell Stock, Haoming Gu, Gregory Stock, Zhu Li, Peter Wolanin
-
Publication number: 20070031909Abstract: The invention relates to methylated proteins that control protein phosphorylation, particularly phosphoesterases, such as PP2A. It relates to screening methods for determining agents that affect methylation of these proteins and thus also modulate the level of phosphorylation of phosphoproteins. It relates as well to the agents and to compositions comprising the agents. In a particular aspect in this regard the invention relates to agents that alter PP2A methylation and that thereby affect phosphorylation of phosphoproteins that play an important role in health or disease, such as the tau protein which is implicated in the etiology of Alzheimer's Disease. The invention further relates to diagnostic methods based on protein methylation levels, to compositions comprising agents for affecting methylation of proteins and for controlling the phosphate complement of phosphoproteins.Type: ApplicationFiled: March 13, 2003Publication date: February 8, 2007Inventors: Gregory Stock, Jeffry Stock, Maxwell Stock, Scott Vafai
-
Publication number: 20060171938Abstract: The invention encompasses novel compositions containing a methylation modifying compound isolated from botanical raw materials, including a fruit of the genus Coffea, and microbial raw materials, methods of making such compositions, and methods of treating or preventing human disease using such compositions. The methylation modifying compound in botanical extracts of the present invention can dramatically increase the level of methylation of PP2A, thus increasing cognitive function, particularly in persons suffering from or prone to developing Alzheimer's disease.Type: ApplicationFiled: February 3, 2006Publication date: August 3, 2006Inventors: Jeffry Stock, Maxwell Stock, Gu Haoming, Gregory Stock, Zhu Li, Peter Wolanin
-
Publication number: 20050277694Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditionsType: ApplicationFiled: June 13, 2005Publication date: December 15, 2005Applicant: Signum Biosciences, Inc.Inventors: Jeffry Stock, Joel Gordon, Maxwell Stock, Greg Stock